Nonmyeloablative Stem Cell Transplant In

Allogeneic transplant with reduced intensity conditioning regimens have recently shown promise in the therapy of MMM.21 A series by Rondelli and colleagues24 of 20 "high-risk" MMM patients (by Lille criteria27) with a median age of 54 years underwent reduced intensity conditioning allogeneic transplant. Survival was 90% at 18 months, with a 10% transplant-related mortality (both from complications of GvHD). Chronic GvHD (>grade II) was present in 50% of evaluable patients. Significant clinical improvement was noted in many, but extent and duration of remission have not yet been published.

0 0

Post a comment